Response to Letter to the Editor: Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations

Affiliations

Free article

Comment

James F Donohue. Respir Med. 2016 Jan.

Free article

. 2016 Jan:110:81.

doi: 10.1016/j.rmed.2015.11.011. Epub 2015 Nov 27.

¹ Department of Medicine, University of North Carolina College of Medicine, Chapel Hill, NC 27599, USA. Electronic address: james_donohue@med.unc.edu.

No abstract available

Comment on

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Donohue JF, et al. Respir Med. 2015 Jul;109(7):870-81. doi: 10.1016/j.rmed.2015.04.018. Epub 2015 May 8. Respir Med. 2015. PMID: 26006754 Clinical Trial.
Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
Banerji D, Patalano F. Banerji D, et al. Respir Med. 2016 Jan;110:79-80. doi: 10.1016/j.rmed.2015.07.009. Epub 2015 Jul 17. Respir Med. 2016. PMID: 26211886 No abstract available.